Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPPL2A | Q8TCT8 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15082086 | 0.94 | ADAMTS4 (0.58) | — | |
| SCHEMBL8238668 | 0.94 | SPPL2A (0.55) | SPPL2A | |
| SCHEMBL1804866 | 0.93 | SPPL2A (0.60) | SPPL2A | |
| SCHEMBL1804868 | 0.93 | SPPL2A (0.60) | SPPL2A | |
| SCHEMBL6099960 | 0.93 | SPPL2A (0.60) | SPPL2A | |
| SCHEMBL1804867 | 0.93 | SPPL2A (0.60) | SPPL2A | |
| SCHEMBL8238222 | 0.92 | SPPL2A (0.53) | SPPL2A | |
| SCHEMBL12512740 | 0.92 | SPPL2A (0.53) | SPPL2A | |
| SCHEMBL13567521 | 0.91 | SPPL2A (0.58) | SPPL2A | |
| SCHEMBL13538009 | 0.91 | SPPL2A (0.58) | SPPL2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100113582-A1 | METHODS AND COMPOSITIONS FOR TREATING HIV INFECTIONS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-05-06 | — | — | US | disclosed |
| US-20080085918-A1 | Fluorogenic; for measuring anti-HIV protease activity of inhibitor; drug resistance; bioavailability; can be used to predict the emergence of drug resistance for a particular replicating biological entity (e.g., a disease-causing cell) in the presence a drug (e.g., an inhibitor) | GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY SECRETARY, DEPARTMEMT OF HEALTH AND (US) | 2008-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113582-A1 | METHODS AND COMPOSITIONS FOR TREATING HIV INFECTIONS | SERPINB1, HPN, PRSS1 | SPPL2A 2411/4885 |
| US-20080085918-A1 | Fluorogenic; for measuring anti-HIV protease activity of inhibitor; drug resistance; bioavailability; can be used to predict the emergence of drug resistance for a particular replicating biological entity (e.g., a disease-causing cell) in the presence a drug (e.g., an inhibitor) | CTSS, CTSE, FURIN | SPPL2A 2290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.